New technologies and alternatives to traditional cosmetic surgery have opened up a huge new market for anti-aging products. Cosmetic facial rejuvenation is no longer the purview of plastic surgeons, but represents a booming cash business for a large number of dermatologist and other practitioners. Botox, dermal fillers, resurfacing modalities, lasers, and other alternatives are creating […]
July 1, 2004
In 2003, the market for monoclonal antibodies in the treatment of cancer is just short of $2.8 billion and growing at a phenomenal rate. The market is fueled by leading products such as Rituxan and Herceptin; however, other products continue to demand more attention each year. This study reviews market data for the years 2001 […]
June 1, 2004
Biologics, or biopharmaceuticals, are synthetic or recombinant versions of natural biologic substances, including proteins such as enzymes or antibodies and nucleic acids such as DNA or RNA. Generic products are non-patented chemical and therapeutic equivalents of brand name drugs. However, biogenerics are not generic biologics, because there can technically be no generic form of biologics. […]
June 1, 2004
Ten years ago, high throughput screening (HTS) was being touted as the answer to improving productivity in drug discovery. If screening thousands of compounds a week was good, screening hundreds of thousands would be even better. This led to the boom in Ultra HTS (UHTS), manufacturing-scale systems, and high-speed automation. Today, reality has begun to […]
June 1, 2004
Molecular diagnostics are seen as being a major breakthrough in medical science. While the technology itself has broad applications to such areas as agricultural bioterrorism and environmental science, medical and medical research applications have provided the primary focus. As a result, great things have been predicted for the development and use of new therapeutics based […]
May 1, 2004
Changing demographics are spurring dynamic growth in the interventional radiology market. The angioplasty balloon, coronary stent, vascular closure, and other associated equipment markets will experience healthy growth over the next 5 years. Persons over the age of 65 will be a major segment of the population in coming years. Chronic diseases and unhealthy habits such […]
April 1, 2004
The recent terrorism events, in addition to the ease of travel that allows infectious diseases to spread, and technology developments drive the renewed interest in clinical and environmental infectious disease diagnostics. The combined public health and bio-terrorism markets of several bacterial and protozoan diseases are estimated to be nearly $100 million. This report, the final […]
April 1, 2004
A host of new and old infectious diseases have emerged on the world stage, presenting familiar and novel challenges to public health officials. New strains of once controlled bacteria, new immunocomprimised patient populations, and new bioterror threats have spurred diagnostics companies to develop new tests and kits to meet the demand. Kalorama has assembled the […]
March 1, 2004
The hard-fought battle over Medicare’s prescription drug benefit is over, but the long-term effects of the new law are still unclear. Exactly who will benefit and by how much? Is it a victory for big pharma? Initial reactions are not always correct, and this examination into the true implications for pharmaceutical markets looks at all […]
March 1, 2004